Factor IX Complex (Human)

Table of contents

  • Brand Names
  • Drug Combinations
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Benefix; Belgium: Benefix, Mononine, Nonafact, Octanine; Bulgaria: Immunine, Octanine F; Cyprus: Benefix; Czech Republic: Immunine, Mononine, Nonafact, Octanine F; Denmark: Benefix; Estonia: Benefix, Immunine, Nonafact; Finland: Benefix, Nonafact, Octanine; France: Benefix; Germany: BeneFIX, Immunine, Mononine, Nonafact; Greece: Benefix, Mononine; Hungary: Humafactor-9, Mononine, Nonafact, Octanine F; Ireland: Benefix, Immunine, Nanotiv, Nonafact; Italy: Benefix; Latvia: Immunine, Nonafact; Lithuania: BeneFIX, Immunine, Nonafact; Malta: Aimafix, Replenine VF; Netherlands: Alphanine, Betafact, Mononine, Nonafact; Poland: Immunine, Nonafact, Octanine F; Portugal: Aimafix, Betafact, Immunine, Mononine, Nanotiv, Nonafact, Octaninef; Romania: Immunine, Nonafact, Octanine F; Slovakia: BeneFIX, Immunine, Mononine, Nonafact, Octanine F; Slovenia: Immunine, Mononine, Octanine F; Spain: Factor IX, Immunine, Mononine, Nanotiv; Sweden: BeneFIX, Immunine, Mononine, Nanotiv, Nonafact; UK: AlphaNine, Mononine, Replenine VF.

North America

Canada: Benefix, Immunine, Mononine; USA: Bebulin VH, Profilnine SD.

Latin America

Argentina: Aimafix D.I., Benefix, Immunine, Octanine F; Mexico: Octanine F, Replenine VF.

Drug combinations

Factor IX, Factor II, Factor VII, and Factor X

Factor IX, Factor II, Factor VII, and Factor X, and Protein C Concentrate (Human)


Pharmacologic Category

Antihemorrhagic Agents; Hemostatics. Antihemophilic Agent. Blood Product Derivative. (ATC-Code: B02BD04; B02BD01).

Mechanism of action

Replaces deficient clotting factor including factor X. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII: C, activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot.

Therapeutic use

Control of bleeding in patients with factor, IX deficiency (hemophilia B or Christmas disease).

Pregnancy and lactiation implications

Unlabeled use

Emergency correction of the coagulopathy of warfarin excess in critical situations.


Liver disease with signs of intravascular coagulation or fibrinolysis. Not for use in factor VII deficiencies, or in patients undergoing elective surgery.

Warnings and precautions

Thrombotic events rarely occur (more likely to occur during postoperative period or in patients with risk factors). Unstable vital signs (respiratory distress or changes in blood pressure or pulse rate) might occur. Use with extreme caution in hepatic impairment. Product of human plasma (may potentially contain infectious agents which could transmit disease).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart